Page 9 - Eric Mcdade News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Longtime St. Louis benefactor Joanne Knight has committed up to $11.5 million to Washington University School of Medicine to support an innovative

Longtime St. Louis benefactor Joanne Knight has committed up to $11.5 million to Washington University School of Medicine in St. Louis to support an innovative clinical trial aimed at preventing Alzheimer’s disease by treating people before the first signs of the illness appear in the brain.

AILSA CHANG, HOST: Doctors can now prescribe a controversial new drug to their patients with Alzheimer's disease. But even medical experts are still trying to figure out which patients should get the drug and how to use it safely. NPR's Jon Hamilton reports from the Alzheimer's Association International Conference in Denver. JON HAMILTON, BYLINE: The drug, called Aduhelm, received a conditional approval from the Food and Drug Administration in June. The approval came despite conflicting evidence on whether the drug actually slows the progression of Alzheimer's. Since then, some experts have s...

16 Dec 2020 BACE inhibitors succeeded in stemming the tide of Aβ production in the brain, but the drugs also slightly dulled cognition and shrank the brain, bringing the trials to a screeching halt. Rather than washing their hands of a failure and moving on, researchers continue to dig through the trial data to find out exactly what happened, and perhaps even to chart a way forward for the drugs. Three recent studies—all led by Michael Egan at Merck—add new insight. Verubecestat triggered a rapid atrophy that did not get worse. This happened in amyloid-rich regions, and did not track wit...